Literature DB >> 10759764

Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin.

H Herfarth1, K Brand, H C Rath, G Rogler, J Schölmerich, W Falk.   

Abstract

In acute DSS-induced colitis nuclear factor (NF)-kappaB-dependent inflammatory cytokines including IL-1 and tumour necrosis factor-alpha (TNF-alpha) are up-regulated. Here we examined the effects of gliotoxin, a fungal metabolite known to inhibit NF-kappaB activity, on cytokine production by a mouse cell system in vitro and on intestinal inflammation and NF-kappaB activation in vivo. In vitro gliotoxin decreased TNF-alpha gene expression and protein production by RAW-264.7 mouse macrophage-like cells stimulated with lipopolysaccharide. In vivo, gliotoxin treatment of mice was begun on day 3 of 5% DSS application dissolved in the drinking water and continued until day 8. Gliotoxin treatment dose-dependently down-regulated colonic inflammation as assessed histologically and in parallel there was a suppression of colonic TNF-alpha and IL-1alpha mRNA expression on day 8 as analysed by semiquantitative reverse transcriptase-polymerase chain reaction (P < 0.01). Furthermore, colonic NF-kappaB DNA-binding activity was increased in DSS-induced colitis and was suppressed by gliotoxin. These results demonstrate the essential role of NF-kappaB in DSS-induced colitis and indicate a molecular approach to the treatment of intestinal inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759764      PMCID: PMC1905603          DOI: 10.1046/j.1365-2249.2000.01184.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  A procedure for Northern blot analysis of native RNA.

Authors:  E W Khandjian; C Méric
Journal:  Anal Biochem       Date:  1986-11-15       Impact factor: 3.365

Review 2.  Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation.

Authors:  W Strober; I J Fuss; R O Ehrhardt; M Neurath; M Boirivant; B R Lúdvíksson
Journal:  Scand J Immunol       Date:  1998-11       Impact factor: 3.487

3.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Authors:  S E Plevy; C J Landers; J Prehn; N M Carramanzana; R L Deem; D Shealy; S R Targan
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

4.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

Authors:  I Okayasu; S Hatakeyama; M Yamada; T Ohkusa; Y Inagaki; R Nakaya
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

5.  Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.

Authors:  G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

Review 6.  Medical therapy of inflammatory bowel disease.

Authors:  P Rutgeerts
Journal:  Digestion       Date:  1998-08       Impact factor: 3.216

7.  Colonic antioxidant status in dextran sulfate-induced colitis in mice.

Authors:  A C Blackburn; W F Doe; G D Buffinton
Journal:  Inflamm Bowel Dis       Date:  1997       Impact factor: 5.325

8.  Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors.

Authors:  C Jobin; C Hellerbrand; L L Licato; D A Brenner; R B Sartor
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

9.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

10.  The effect of gliotoxin upon macrophage function.

Authors:  R D Eichner; M Al Salami; P R Wood; A Müllbacher
Journal:  Int J Immunopharmacol       Date:  1986
View more
  28 in total

Review 1.  The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

2.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

Review 3.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

4.  Enhanced human beta-defensin-2 (hBD-2) expression by corticosteroids is independent of NF-kappaB in colonic epithelial cells (CaCo2).

Authors:  T Witthöft; C S Pilz; K Fellermann; M Nitschke; E F Stange; D Ludwig
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

5.  Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats.

Authors:  Ping Zheng; Feng-Li Niu; Wen-Zhong Liu; Yao Shi; Lun-Gen Lu
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

6.  Exacerbation of dextran sulfate sodium-induced colitis by dietary iron supplementation: role of NF-kappaB.

Authors:  Julie C Carrier; Elaheh Aghdassi; Khursheed Jeejeebhoy; Johane P Allard
Journal:  Int J Colorectal Dis       Date:  2005-08-23       Impact factor: 2.571

7.  Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

8.  Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.

Authors:  Akira Sakata; Takashi Ochiai; Hiroshi Shimeno; Sadao Hikishima; Tsutomu Yokomatsu; Shiroshi Shibuya; Akihisa Toda; Reiko Eyanagi; Shinji Soeda
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

9.  ROS, Hsp27, and IKKbeta mediate dextran sodium sulfate (DSS) activation of IkappaBa, NFkappaB, and IL-8.

Authors:  Sumit Bhattacharyya; Pradeep K Dudeja; Joanne K Tobacman
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

10.  Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice.

Authors:  Y W Chung; J H Choi; T-Y Oh; C S Eun; D S Han
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.